Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 Update

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 4, 2014, Pages 376-382

  Crews, K R ^a   Gaedigk, A ^b,c   Dunnenberger, H M ^a   Leeder, J S ^b,c   Klein, T E ^d   Caudle, K E ^a   Haidar, C E ^a   Shen, D D ^e   Callaghan, J T ^f,g   Sadhasivam, S ^h   Prows, C A ^h   Kharasch, E D ⁱ   Skaar, T C ^f  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f INDIANA UNIVERSITY   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CODEINE; CODEINE 6 GLUCURONIDE; CYTOCHROME P450 2D6; FENTANYL; GLUCURONOSYLTRANSFERASE 2B7; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE 6 GLUCURONIDE; NORCODEINE; O DEMETHYLASE; O NORTRAMADOL; OXYCODONE; OXYMORPHONE; TRAMADOL;

ADENOIDECTOMY; ALLELE; ANALGESIC ACTIVITY; ARTICLE; BREAST FEEDING; BREAST MILK; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; GENE DOSAGE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GLUCURONIDATION; HETEROZYGOTE; HUMAN; INCIDENTAL FINDING; MAXIMUM PLASMA CONCENTRATION; PHARMACOGENETICS; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TONSILLECTOMY;

ANALGESICS, OPIOID; CODEINE; CYTOCHROME P-450 CYP2D6; GENETIC TESTING; GENOTYPE; HUMANS; MORPHINE; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84897022750     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.254     Document Type: Article

References (40)

1. Crews, K.R. et al.; Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91, 321-326 (2012.
2. Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M.L., Sjöqvist, F. & Ingelman-Sundberg, M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 90, 11825-11829 (1993.
3. Gaedigk, A., Simon, S.D., Pearce, R.E., Bradford, L.D., Kennedy, M.J. & Leeder, J.S. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234-242 (2008.
4. Borges, S. et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J. Clin. Pharmacol. 50, 450-458 (2010.
5. Gaedigk, A., Gotschall, R.R., Forbes, N.S., Simon, S.D., Kearns, G.L. & Leeder, J.S. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9, 669-682 (1999.
6. Peñas-Lledó, E.M., Blasco-Fontecilla, H., Dorado, P., Vaquero-Lorenzo, C., Baca-García, E & Llerena, A. CYP2D6 and the severity of suicide attempts. Pharmacogenomics 13, 179-184 (2012.
7. Zhou, L.P., Luan, H., Dong, X.H., Jin, G.J., Man, D.L. & Shang, H. Genetic variants of CYP2D6 gene and cancer risk: A HuGE systematic review and meta-Analysis. Asian Pac. J. Cancer Prev. 13, 3165-3172 (2012.
8. Volpe, D.A. et al. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regul. Toxicol. Pharmacol. 59, 385-390 (2011.
9. Thorn, C.F., Klein, T.E. & Altman, R.B. Codeine and morphine pathway. Pharmacogenet. Genomics 19, 556-558 (2009.
10. Gasche, Y. et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351, 2827-2831 (2004.
11. Eckhardt, K., Li, S., Ammon, S., Schänzle, G., Mikus, G& Eichelbaum, M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 76, 27-33 (1998.
12. Lötsch, J., Rohrbacher, M., Schmidt, H., Doehring, A., Brockmöller, J & Geisslinger, G. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiatioñ Pain 144, 119-124 (2009.
13. Mikus, G. et al. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Clin. Pharmacol. Ther. 61, 459-466 (1997.
14. Kirchheiner, J et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 7, 257-265 (2007.
15. Kelly, L.E et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics 129, e1343-e1347 (2012.
16. Dalén, P., Frengell, C., Dahl, M.L. & Sjöqvist, F. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther. Drug Monit. 19, 543-544 (1997.
17. Ciszkowski, C., Madadi, P., Phillips, M.S., Lauwers, A.E. & Koren, G. Codeine, ultrarapid-metabolism genotype, and postoperative death. N. Engl. J. Med. 361, 827-828 (2009.
18. Stamer, U.M., Musshoff, F., Kobilay, M., Madea, B., Hoeft, A. & Stuber, F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin. Pharmacol. Ther. 82, 41-47 (2007.
19. Lalovic, B., Kharasch, E., Hoffer, C., Risler, L., Liu-Chen, L.Y. & Shen, D.D. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clin. Pharmacol. Ther. 79, 461-479 (2006.
20. Poulsen, L., Arendt-Nielsen, L., Brøsen, K. & Sindrup, S.H. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin. Pharmacol. Ther. 60, 636-644 (1996.
21. Stamer, U.M et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 105, 231-238 (2003.
22. Kirchheiner, J., Keulen, J.T., Bauer, S., Roots, I. & Brockmöller, J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J. Clin. Psychopharmacol. 28, 78-83 (2008.
23. Otton, S.V., Schadel, M., Cheung, S.W., Kaplan, H.L., Busto, U.E. & Sellers, E.M. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin. Pharmacol. Ther. 54, 463-472 (1993.
24. Kaplan, H.L. et al. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J. Pharmacol. Exp. Ther. 281, 103-108 (1997.
25. Davis, M.P., Varga, J., Dickerson, D., Walsh, D., LeGrand, S.B. & Lagman, R. Normal-release and controlled-release oxycodone: Pharmacokinetics, pharmacodynamics, and controversy. Support. Care Cancer 11, 84-92 (2003.
26. Zwisler, S.T., Enggaard, T.P., Mikkelsen, S., Brosen, K. & Sindrup, S.H. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol. Scand. 54, 232-240 (2010.
27. Andreassen, T.N. et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer paiñ A cross-sectional multicentre study. Eur. J. Clin. Pharmacol. 68, 55-64 (2012.
28. Zwisler, S.T. et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin. Pharmacol. Toxicol. 104, 335-344 (2009.
29. Samer, C.F. et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br. J. Pharmacol. 160, 919-930 (2010.
30. Rollason, V., Samer, C., Piguet, V., Dayer, P & Desmeules, J. Pharmacogenetics of analgesics: Toward the individualization of prescription. Pharmacogenomics 9, 905-933 (2008.
31. Stevens, J.C. et al. Developmental changes in human liver CYP2D6 expression. Drug Metab. Dispos. 36, 1587-1593 (2008.
32. Blake, M.J. et al. Ontogeny of dextromethorphan O-And N-demethylation in the first year of life. Clin. Pharmacol. Ther. 81, 510-516 (2007.
33. Allegaert, K., Rochette, A. & Veyckemans, F. Developmental pharmacology of tramadol during infancy: Ontogeny, pharmacogenetics and elimination clearance. Paediatr. Anaesth. 21, 266-273 (2011.
34. Willmann, S., Edginton, A.N., Coboeken, K., Ahr, G. & Lippert, J. Risk to the breast-fed neonate from codeine treatment to the mother: A quantitative mechanistic modeling study. Clin. Pharmacol. Ther. 86, 634-643 (2009.
35. Madadi, P. et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: A case-control study. Clin. Pharmacol. Ther. 85, 31-35 (2009.
36. Koren, G., Cairns, J., Chitayat, D., Gaedigk, A. & Leeder, S.J. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368, 704 (2006.
37. Kelly, L.E et al. A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk. PLoS ONE 8, e70073 (2013.
38. US Food and Drug Administration FDA Drug Safety Communication: Codeine use in certain children after tonsillectomy and/or adenoidectomy may lead to rare, but life-Threatening adverse events or death. http://www.fda.gov/ Drugs/DrugSafety/ucm313631.htm (2012.
39. Voronov, P., Przybylo, H.J. & Jagannathan, N. Apnea in a child after oral codeine: A genetic variant-An ultra-rapid metabolizer. Paediatr. Anaesth. 17, 684-687 (2007.
40. US Food and Drug Administration Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy. FDA Drug Safety Communication. http://www.fda.gov/drugs/ drugsafety/ucm339112.htm (2013.